Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 16, 2025

Primary Completion Date

March 7, 2028

Study Completion Date

June 15, 2028

Conditions
Graft-Versus-Host Disease(GVHD)
Interventions
DRUG

Omega-3 Lipid Emulsion

Intravenous Omega-3 lipid emulsion administered at a dose of 2 mL/kg/day (equivalent to 0.2 g/kg of fish oil), starting from the conditioning phase prior to hematopoietic stem cell infusion and continuing daily until neutrophil and platelet engraftment or up to Day +35 post-transplantation. The emulsion is infused over 4-6 hours and combined with medium- and long-chain triglyceride emulsion as part of parenteral nutrition.

Trial Locations (1)

353000

The First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

Fujian Medical University

OTHER